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Abstract
Background: At present, there are no registered products for the treatment of subchondral Bone Marrow Edema
Lesion (BML) and associated knee pain. Patients who do not respond to current anti-inflammatory therapies are left
with limited treatment options, and may resort to operative management with Total Knee Arthroplasty (TKA). We
report the use of Pentosan Polysulphate Sodium (PPS) for the treatment of BMLs of the knee.
Case presentation: We report the case of a 70-year-old female with knee osteoarthritis presenting with a high
level of knee pain, scoring 8 on the Numerical Rating Scale (NRS), and functional limitation demonstrating a poor
Lysholm Knee Score of 37. MRI scans of the knee revealed subchondral BML in the medial femoral condyle and
medial tibial plateau. The patient was administered a course of Pentosan Polysulphate Sodium (PPS) intramuscularly
twice weekly, for 3 weeks. MRI scans 2 weeks post-treatment showed complete resolution of the bone marrow
edema at the medial femoral condyle and medial tibial plateau with concomitant recovery from pain (NRS pain
score of 0), and a 43% improvement of the Lysholm Knee Score. In addition, marked reduction in joint effusion was
also demonstrated in the MRI scan post PPS therapy.
Conclusion: The MRI interpretations demonstrate improved clinical outcome measures ensuing therapeutic intervention
with PPS, and warranting further investigation into the efficacy of PPS in the treatment of BML associated pain
and dysfunction in the osteoarthritic population via randomized controlled trial, or equivalent rigorous methodological
technique.
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Background
Bone Marrow Edema Lesions (BMLs) are changes that
occur in the subchondral bone and are detected by Mag-
netic Resonance Imaging (MRI), depicting the severity of
symptoms including pain [1–3] and cartilage degene-
ration [4–7] in osteoarthritic patients. BMLs are gener-
ally evaluated using fat-suppressed proton density or
T2-weighted sequences. In fat suppressed T2-weighted
and fat suppressed proton density weighted sequences,
BMLs appear as hyper-intense areas in subchondral
bone and in T1-weighted sequences they appear as
hypo-intense signals [8]. The MRI signals related to the
BML are thought to arise from an increase in concentra-
tion of blood and interstitial fluids (including infiltrating
macrophages) in areas of trabecular microfractures and
collapse within the bone marrow [8]. Improved spatial
resolution and multiplanar reconstructions provide a po-
tential role of 3D fast spin echo sequences, particularly
for imaging of cartilage [9].
Increasing evidence supports the notion that BMLs play
an important role in the pathogenesis of knee osteoarth-
ritis, particularly in established disease where BMLs are
associated with knee pain [2], radiological progression of
knee osteoarthritis [10] and cartilage loss based on MRI
[5, 11]. In regards to progressive osteoarthritis, data have
suggested that BMLs are more likely to persist and enlarge
in size with an associated increase in cartilage loss [5].
Furthermore, the severity of BMLs has shown to correlate
with the increasing risk of knee arthroplasty [12]. The
strong association of BMLs with pain and loss of cartilage
has heightened pharmaceutical interest to target this
structural lesion for monitoring progression of knee osteo-
arthritis and therapeutic effects [13–15].
Pentosan Polysulphate Sodium (PPS) is a semi-synthetic
drug manufactured from beech-wood hemicellulose by
sulphate esterification of the xylopyranose hydroxyl
groups [16]. PPS has been used in the treatment of horses
with osteoarthritis, and demonstrated beneficial effects on
the cartilage fibrillation and synovial fluid concentrations
[17, 18]. In addition, further research into the anti-
inflammatory properties of PPS have concluded (i) in-
hibition of the cartilage degrading enzymes which are
upregulated post-acute injury [19]; (ii) inhibition of the
nuclear translocation of NF-kappaB and the regulation
of transcription of the pro-inflammatory cytokines
TNF-alpha and interleukin IL-1 beta [20]; (iii) anti-
thrombotic and antilipidemic effects which may assist
with improved microvascular circulation in the sub-
chondral bone [21] and considered to be mechanistic-
ally relevant in resolving BML. Furthermore, the safety
profile of PPS has been further validated in two clinical
trials in osteoarthritis patients [16, 22].
In this report we have observed the anti-inflammatory,
disease modifying properties of PPS that potentially
resulted in the rapid reduction of BML and joint effu-
sion in an osteoarthritic patient.
Case presentation
A 70-year-old female with a history of osteoarthritis and
arthroscopic partial medial meniscectomy presented
with pain of the left knee and was on a waiting list for
Total Knee Arthroplasty (TKA). The patient had failed
to respond to intra-articular cortisol administration at
the time of arthroscopy. The MRI scan of the knee,
using a 3-Tesla proton density turbo spin echo fat satu-
rated acquisition with TR 3000 ms TE 30 ms, demon-
strated subchondral BML associated with focal full
thickness chondral defects at the medial aspects of the
weight bearing medial femoral condyle and medial tibial
plateau (Fig. 1). The BML in the medial femoral condyle
measured 11 × 7 × 12 mm (CC x transverse x AP) and
the medial tibial plateau BML measured 8 × 8 × 8 mm
(CC x transverse x AP). In addition, the axial proton
density fat saturated imaging at the level of suprapatellar
pouch revealed a knee effusion and a recurrent tear of
the medial meniscus (body and posterior horn). Follow-
ing patient consent, the pain assessment score was de-
termined by the Numerical Rating Scale (NRS), an 11-
point scale with endpoints of ‘a state of no pain (“0”)’
and ‘the worst pain imaginable (“10”)’ [23]. Functional
capacity was assessed using the Lysholm knee score [24].
At pre-treatment, the NRS pain score was severe with a
score of 8 out of 10 (Scale range: 0 to 10) and the
Lysholm Knee Score was 37 out of 100, reflecting poor
knee function indicated by problems in stair climbing
and limping.
As PPS is a weak anticoagulant with 1/15 the activity
of heparin, the patient was monitored for safety by as-
sessments of complete blood count, Activated Partial
Thromboplastin Time (APTT), prothrombin time, liver
function tests, renal function tests and serum calcium
prior to commencement of treatment and periodically
during treatment with PPS. The clinical status of the pa-
tient was checked regularly throughout the course of the
treatment and follow up period.
After evaluation, the patient was considered suitable
for PPS treatment. Since the injectable form of PPS is
not a registered product in Australia for the treatment
of BMLs, approval to use PPS as treatment for the pa-
tient was acquired from the Department of Health -
Therapeutic Goods Administration, Australian Govern-
ment under the Special Access Scheme. The patient was
administered 2 mg/kg of PPS twice weekly with a mini-
mum of 3 and a maximum of 4 days between dosages.
Six intramuscular injections were administered into the
gluteus maximus muscle over a 3-week period (2 injec-
tions per week). During the course of PPS treatment the
patient abstained from NSAIDs and did not receive any
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additional therapy. Three follow-up appointments were
made at 10, 24 and 38 days post-completion of injection
regimen. Five weeks after the first PPS injection, MRI
scans were performed using a 3-Tesla proton density fat
saturated SPACE acquisition with TR 1200 ms TE 28 ms
which demonstrated complete resolution of the BMLs at
the medial femoral condyle and medial tibial plateau. In
addition, the axial imaging at the level of the suprapatel-
lar pouch demonstrated reduction in the size of the knee
effusion. The patient displayed a marked functional im-
provement of 43% in the Lysholm Knee score at 4 weeks
after the last injection, reporting a score of 65. Similarly,
a robust recovery of pain was demonstrated, with the pa-
tient reporting a pain score of 0 on the NRS. During the
PPS treatment and follow-up period, the patient did not
present with any drug-related or nondrug-related ad-
verse responses.
Discussion
The MRI findings performed using a 3-Tesla proton
density fat saturated SPACE acquisition with TR
1200 ms TE 28 ms demonstrated that a course of intra-
muscular PPS produced complete resolution of the BML
at the medial femoral condyle and medial tibial plateau.
In addition, the axial imaging at the level of the suprapa-
tellar pouch demonstrated reduction in the size of the
knee effusion. The effects of PPS may be attributed to
the multiple pharmaceutical actions related to its anti-
inflammatory effects on IL-1 beta and TNF-alpha [20].
In addition, its inhibition of extracellular matrix
degrading enzymes such as ADAMTS and MMPs [19]
and improvement of microcirculation may have assisted
in the reduction of cellular infiltration and minimization
of the intra-osseous pressure in the bone marrow with
alleviation of pain [21]. Extensive supportive data on the
anti-inflammatory effects of PPS have been reported in
animal and veterinary studies showing beneficial effects
on the cartilage fibrillation and synovial fluid concentra-
tions in dogs and osteoarthritic horses [17, 18]. Further-
more, a low incidence of side effects was observed in the
treatment of dogs with osteoarthritis and significant re-
duction in cartilage degradation [25]. PPS efficacy was
also shown in rat models of arthritis with the rodents
showing reduced joint swelling and inflammation [26].
In support of improved microcirculation, PPS adminis-
tration in rabbit and canine models exhibited increased
blood flow through subchondral capillaries of osteoarth-
ritis joints and bone cell nutrition [26].
The patient did not report any adverse effects due to
PPS administration which supports the safety profile of
this agent as reported in previous clinical trials [17, 22]
conducted in osteoarthritic subjects. However, the new
finding in this case report not previously reported were
the effects of PPS on the MRI diagnostic features of
subchondral BML and joint effusions. Moreover, the
observed improvement in knee function in this patient
may be ascribed to the chondro-protective effects of
PPS [21, 22].
Current treatment options for BML associated osteo-
arthritis are diverse with limited reports of improved
Fig. 1 Pre-treatment 3T proton density fat saturated images in coronal (a) and sagittal (b) planes demonstrating medial compartment bone
edema, more pronounced on the tibial side. Axial (c) proton density fat saturated imaging at the level of suprapatellar pouch demonstrating a knee
effusion. Corresponding post-treatment 3T proton density fat saturated images in coronal (d) and sagittal (e) planes demonstrating resolution of
medial compartment bone edema. Axial (f) proton density fat saturated imaging at the level of suprapatellar pouch demonstrating reduction in size of
knee effusion
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clinical outcome. The standard treatment of BML in
osteoarthritic patients consists of analgesic or anti-
inflammatory medications combined with reduced
weight-bearing and physical therapy until symptoms
reduce or resolve [27]. However, non-steroidal anti-
inflammatory drugs (NSAIDs) and corticosteroids have
been found to have negative effects on bone healing and
the metabolism of cartilage [28–31]. As reviewed by
O’Mahony [30] the risk of fracture, both traumatic and
spontaneous, is increased in those subjects that take con-
tinuous corticosteroid therapy. Therefore, PPS may be a
suitable pharmaceutical option to NSAIDs and corticoste-
roids with potential disease modifying activity. Treatment
by PPS in this report demonstrated complete reduction in
BML, with no post-treatment adverse events reported on
follow-up with the patient.
It should be noted that different MRI sequences were
used pre- and post-treatment. This occurred as the pa-
tient’s initial scan (a 2D proton density study) was an ex-
tensive diagnostic scan looking at all structures, whereas
the follow-up scan (a 3D proton density SPACE study)
was a more limited study specifically utilized for asses-
sing BMLs in an efficient manner. Although there is a
paucity in the literature comparing sensitivities of the
two sequences in relation to BMLs and effusions, the
SPACE sequence enables acquisition of high resolution
3D datasets with contrasts similar to those obtained
from 2D proton density imaging [32]. Given this, it is
highly unlikely the use of slightly different MRI se-
quences in the pre- and post-treatment MRI studies
would have biased the result.
Conclusion
Results from this case report implicate the potential ef-
fectiveness of PPS as a treatment option for osteoarth-
ritic patients with BML and joint effusion. Given such
findings, we recommend that future research seek to fur-
ther investigate the efficacy of PPS in the treatment of
BML associated pain and dysfunction in the osteoarth-
ritic population via randomized controlled trial, or
equivalent rigorous methodological techniques.
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